摘要
目的:研究国产赖诺普利片在健康人体内的药动学及其生物等效性。方法:20例健康受试者单剂量交叉口服20 mg赖诺普利供试制剂(国产制剂)或参比制剂(进口制剂)后,采用LC-MS测定人体血浆中不同时间点赖诺普利的浓度,计算其药动学参数和相对生物利用度,评价2制剂的生物等效性。结果:赖诺普利供试制剂和参比制剂主要药动学参数C_(max)分别为(93.85±30.79)和(101.56±35.84)ng.mL^(-1),AUC_(0~96h)分别为(1690.26±528.20)和(1729.13±568.90)ng·h·mL^(-1),T_(max)分别为(6.6±0.9)和(6.3±1.0)h,t_(1/2)分别为(16.28±2.51)和(15.87±2.80)h。2制剂主要药动学参数经统计学检验无显著性差异。国产制剂的相对生物利用度为(98.6±8,7)%。结论:国产赖诺普利片与进口制剂具有生物等效性。
Objective: To study the pharmacokinetics and bioequivalence of lisinopril tablets made in China (test) vs. imported (reference). Methods: 20 healthy male volunteers were received a single crossover dose of the test tablets (20 mg) or reference tablets. The plasma samples were collected from the volunteers to measure the blood lisinopril concentration using a LC-MS method. Results: The pharmacokinetic parameters of test and reference lisinopril were Cmax (93.85 ± 30.79) vs. ( 101.56± 35.84)ng·mL^-1 ; AUC0.90-h ( 1 690.26± 528. 20) vs. ( 1 729. 13 ± 568.90) ng· h· mL^-1 ; Tmax (6.6 ± 0.9) vs. (6.3±1.0) h; and t1/2(16.28±2.51) vs, (15.87±2.80)h, respectively; the Pvalues of these parameters showed no significant difference. The relative bioavailability of the test lisinopril was (98.6 ±+ 8.7) %. Conclusion: The test lisinopril is bioequivalent to reference lisinopril.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2006年第22期1972-1974,共3页
Chinese Journal of New Drugs
关键词
赖诺普利
高效液相色谱-质谱法
生物等效性
lisinopril
high performance liquid chromatography coupled to tandem mass spectrometry
bioequivalence